Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Metabolic Disorders Infectious Diseases Cancer

Shionogi outlines plans for Europe

This article was originally published in Scrip

  • News

Executive Summary

As part of its ambitions to build a global presence, the Japanese firm Shionogi now wants to make its mark in Europe and has opened offices in London. Takashi Takenoshita, Shionogi's head of the new European operations, joined Scrip in the podcast studio to discuss where the firm plans to go and how it hopes to succeed.

You may also be interested in...



Voluntary EU Joint Clinical Assessments ‘Risk Access To Medicines’

Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.

Future Unclear For EU Mandatory Joint Clinical Assessment Plans

Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.

Ibrance Joins Rival CDK4/6 Inhibitors In English Cancer Drugs Fund

Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.

Table

View full table

Topics

Related Companies

Tags:
Metabolic Disorders Infectious Diseases Cancer
UsernamePublicRestriction

Register

SC018504

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By